We currently have many active studies and we continually have a number of trials in the developmental stage. The studies range from new ophthalmic devices to treat blepharospasm to retinal gene therapy for inherited genetic disease. At the Oxford Eye Hospital, we are incredibly fortunate to have a number of world class ophthalmologists who devote their time & expertise to clinical trials, across a variety of specialities.
If you are interested in learning more about the studies featured please click on the circle icons below or get in touch via our contact page.
FOCUS: A study to test a new treatment for dry AMD.
Investigation of protein defects in retinal degenerations: This is a five year study assessing patients diagnosed with Retinal Degeneration.
MACTEL: A study to test a The Natural History Observation and Registry Study (NHOR)
MACTEL PHASE 3- NTMT-03: A study to test a new treatment for MACTEL.
PERCIEVE: This is a global non-interventional registry-based, post-authorization study (PASS) in paediatric and adult patients who have received Luxturna® sub-retinal injections in a real-world setting.
PressOp™ A new spectacle mounted device designed by clinicians to help individuals with Blepharospasm.
Reneuron: A study to test a new treatment for Retinitis Pigmentosa.
SANDMAN: A randomised placebo-controlled trial to assess the effect of melatonin on circadian sleep-wake disturbances in ocular disease.
SCOPE: A natural history study in genetically defined patients with geographic atrophy secondary to age-related macular degeneration.
SeaSTAR: A new treatment for Stargardt disease (STGD).
